Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX With or Without Bevacizumab in High-Risk Stage II Colon Cancer
NCT00217737Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of bevacizumab in colon cancer, sponsored by National Cancer Institute. Started Sep 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00217737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00217737.